Intermittent epoprostenol infusions in systemic lupus erythematosus associated pulmonary hypertension - A series of three cases

Annals of the Academy of Medicine Singapore

Volumn 32, Issue 1, 2003, Pages 118-121

  Kong, K O ^a   Badsha, H ^a   Thumboo, J ^a   Chng, H H ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Connective tissue diseases; Epoprostenol; Pulmonary hypertension; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; PROSTACYCLIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLIC; DISEASE ASSOCIATION; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPOTENSION; MALE; NAUSEA; PULMONARY HYPERTENSION; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME SERIES ANALYSIS; TREATMENT OUTCOME; VASCULAR ACCESS; VOMITING;

EID: 0037261439     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pan T L, Thumboo J, Boey M L. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000; 9:338-42.
2. Simonson J S, Schiller N B, Petri M, Hellmann D B. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989; 16:918-25.
3. Quismorio F P Jr., Sharma O, Koss M, Boylen T, Edmiston A W, Thornton P J, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13:349-59.
4. Orens J B, Martinez F J, Lynch J P 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 20:159-93.
5. Christman B W, McPherson C D, Newman J H, King G A, Bernard G R, Groves B M, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-5.
6. Barst R J, Rubin L J, Long W A, McGoon M D, Rich S, Badesch D B, et al. A comparison ofcontinuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302.
7. Shapiro S M, Oudiz R J, Cao T, Romano M A, Beckmann X J, Georgiou D, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30:343-9.
8. Humbert M, Sanchez O, Fartoukh M, Jagot J L, Sitbon O, Simonneau G. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). Chest 1998; 114(1 Suppl):80S-82S.
9. Badesch D B, Tapson V F, McGoon M D, Brundage B H, Rubin L J, Wigley F M, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425-34.
10. Robbins I M, Gaine S P, Schilz R, Tapson V F, Rubin L J, Loyd J E. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 117:14-8.
11. Ignaszewski A P, Percy J S, Humen D P. Successful treatment of pulmonary hypertension associated with systemic lupus erythematosus with prostaglandin 12 and prostaglandin El. J Rheumatol 1993; 20: 595-6.
12. Bartosik I, Eskilsson J, Scheja A, Akesson A. Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma - a pilot study. Br J Rheumatol 1996; 35:1187-8.
13. Mok M Y, Tse H F, Lau C S. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Lupus 1999; 8:328-31.
14. Tan E M, Cohen A S, Fries J F, Masi A T, McShane D J, Rothfield N F, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
15. Wharton J, Davie N, Upton P D, Yacoub M H, Polak J M, Morrell N W. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000; 102:3130-6.
16. Tam L S, Li E K. Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. Lupus 1998; 7:495-7.
17. Gonzalez-Lopez L C-M E, Celis A, Sanchez A, Salazar-Paramo M, Garcia-Gonzalez C, Garcia-De la Torre I, et al. Efficacy of cyclophosphamide in patients with systemic lupus erythematosus and pulmonary hypertension. Arthritis Rheum 2000; 43(9 Suppl):S242.
18. Belch J J, Newman P, Drury J K, McKenzie F, Capell H, Leiberman P, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet 1983; 1:313-5.
19. Rubin L J. Primary pulmonary hypertension. N Engl J Med 1997; 336:111-7.
20. Hoeper M M, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-70.
21. Horn E M, Barst R J, Poon M. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 118:1229-30.